| 2022-LEE-69581 | |
| Ocular drug delivery is very challenging due to the complex and sensitive structure of the eye. Researchers at Purdue University have developed a minimally invasive and effective ocular drug delivery platform. This method enables long term sustained release of therapeutic ocular drugs via a tear-soluble contact lens that leaves behind biodegradable silicon nanoneedles. The tear-soluble contact lens provides an optimal curvature to fit the cornea and it is degraded in less than a minute, enabling initial short-term release of anti-inflammatory drugs and long-term release of therapeutic drugs. This technology directly benefits patients undergoing treatment for chronic diseases or injuries, including glaucoma, cataract, and graft rejection. Advantages Minimally invasive - Long term sustained release - Initial burst release of anti-inflammatory - Long-term release of therapeutic drugs - Demonstrated biosafety and efficacy in lab testing Applications - Ocular drug delivery - Treatments for glaucoma, cataract, and graft rejection Technology Validation: This technology has been validated for efficacy and safety through successful in vivo testing in a rabbit corneal neovascularization (CNV) model. |
|
|
|
|
Oct 10, 2022
PCT-Gov. Funding
WO
(None)
(None)
Oct 8, 2021
Provisional-Gov. Funding
United States
(None)
(None)
|
|
|
Purdue Office of Technology Commercialization The Convergence Center 101 Foundry Drive, Suite 2500 West Lafayette, IN 47906 Phone: (765) 588-3475 Fax: (765) 463-3486 Email: otcip@prf.org |
